Whether the type of BMPR2 mutation alters the PAH prognosis remains controversial, as studies comparing prognoses in patients with truncating and missense mutations have yielded divergent results [19], [20]. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.